[Clinical evaluation of carbenicillin in a daily dose of 10 g in chronic airway infections].
Carbenicillin (CBPC) was evaluated in 4 patients with chronic airway infections and 2 with infections secondary to lung cancer. The daily dose of CBPC was 10 g for all patients. The following results were obtained. Three out of 4 patients with chronic airway infections showed good response. Both cases with infection secondary to lung cancer showed good response. The overall effectiveness rate was 83.3%. There were no side effects or abnormal laboratory values related to carbenicillin therapy. CBPC is still considered to be a drug of choice for the initial acute exacerbation of chronic airway infection and for infections secondary to lung cancer.